Trials / Unknown
UnknownNCT05060263
A Study of of HOT1030 in Patients With Advanced Solid Tumors
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT1030 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT-1030 in Patients with Advanced Solid Tumors
Detailed description
This study is an open-label, Phase 1, study to evaluate the safety, tolerability, PK, and PD profiles of HOT-1030 as a monotherapy to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HOT-1030 | HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection |
Timeline
- Start date
- 2021-03-12
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2021-09-29
- Last updated
- 2021-09-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05060263. Inclusion in this directory is not an endorsement.